A Multicenter Randomized Double-Blind Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)
Learn More About This Study
